Skip to main content

Lemtrada use restricted during EMA review

The European Medicines Agency (EMA) has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of a range of potentially serious side effects. These side effects may cause problems with the heart and blood vessels with the medicine, including serious cases.

As a temporary measure while the review is ongoing, the EMA recommends that Lemtrada should only be started in adults with relapsing-remitting multiple sclerosis that is highly active despite treatment with at least two disease-modifying therapies (a type of multiple sclerosis medicine) or where other disease-modifying therapies cannot be used. Patients being treated with Lemtrada who are benefitting from it may continue treatment in consultation with their doctor. While the review is ongoing, Lemtrada will only be prescribed to new patients if other medicines have not worked or are not suitable.

An in-depth review of Lemtrada is ongoing and further information will be provided as soon as it is available.You can visit the EMA website for more information. 

Speak with your doctor if you have questions or concerns about your treatment. 

Source: EMA, 17/04/19

Sub button for news stories - NP.jpg